Peter Barrett

Peter Barrett is a partner at Atlas Venture and has been involved in the creation of several novel therapeutic and drug discovery platform companies. He is also a Senior Fellow at Harvard Business School, where he teaches Commercializing Science to second-year MBA students and is the faculty chair of the key advisory board of the Blavatnik Fellowship Program.

Peter is currently chairman of Synlogic (NASDAQ: SYBX) and Obsidian Therapeutics, and also serves on the board of Larimar (NASDAQ: LRMR). He previously served on the boards of past Atlas companies Vitae Pharmaceuticals (NASDAQ: VTAE; acquired by Allergan), Stromedix (acquired by Biogen), Novamed (acquired by Sciclone), Alnylam (NASDAQ: ALNY), Harbour Antibodies (acquired by Harbour Biomed), Momenta (NASDAQ: MNTA), Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), Infacare (acquired by Mallinckrodt), Archemix (acquired by Baxter) and a number of other ventures.

Prior to joining Atlas Peter was co-founder, executive vice president, and chief business officer of Celera Genomics, which announced the first successful sequencing of the human genome in 2001. While at Celera, Peter led strategic alliances, acquisitions, and business strategy and helped launch it as a public company in 1999.